Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 90

1.

Neuregulin Signaling is a Mechanism of Therapeutic Resistance in Head and Neck Squamous Cell Carcinoma.

Baro M, Lopez Sambrooks C, Burtness BA, Lemmon MA, Contessa JN.

Mol Cancer Ther. 2019 Aug 6. pii: molcanther.0163.2019. doi: 10.1158/1535-7163.MCT-19-0163. [Epub ahead of print]

PMID:
31387891
2.

The EGFR Exon 19 Mutant L747-A750>P Exhibits Distinct Sensitivity to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma.

Truini A, Starrett JH, Stewart TF, Ashtekar KD, Walther Z, Wurtz A, Lu D, Park JH, DeVeaux M, Song X, Gettinger S, Zelterman D, Lemmon MA, Goldberg SB, Politi K.

Clin Cancer Res. 2019 Jun 10. pii: clincanres.0780.2019. doi: 10.1158/1078-0432.CCR-19-0780. [Epub ahead of print]

PMID:
31182434
3.

Computational algorithms for in silico profiling of activating mutations in cancer.

Jordan EJ, Patil K, Suresh K, Park JH, Mosse YP, Lemmon MA, Radhakrishnan R.

Cell Mol Life Sci. 2019 Jul;76(14):2663-2679. doi: 10.1007/s00018-019-03097-2. Epub 2019 Apr 13. Review.

PMID:
30982079
4.

Non-acylated Wnts Can Promote Signaling.

Speer KF, Sommer A, Tajer B, Mullins MC, Klein PS, Lemmon MA.

Cell Rep. 2019 Jan 22;26(4):875-883.e5. doi: 10.1016/j.celrep.2018.12.104.

5.

Flipping ATP to AMPlify Kinase Functions.

Sheetz JB, Lemmon MA.

Cell. 2018 Oct 18;175(3):641-642. doi: 10.1016/j.cell.2018.10.011.

PMID:
30340038
6.

Smoothening out the patches.

Sommer A, Lemmon MA.

Science. 2018 Oct 5;362(6410):26-27. doi: 10.1126/science.aav1025. No abstract available.

PMID:
30287647
7.

Structural Basis for MARK1 Kinase Autoinhibition by Its KA1 Domain.

Emptage RP, Lemmon MA, Ferguson KM, Marmorstein R.

Structure. 2018 Aug 7;26(8):1137-1143.e3. doi: 10.1016/j.str.2018.05.008. Epub 2018 Jun 28.

8.

Regulation of Kinase Activity in the Caenorhabditis elegans EGF Receptor, LET-23.

Liu L, Thaker TM, Freed DM, Frazier N, Malhotra K, Lemmon MA, Jura N.

Structure. 2018 Feb 6;26(2):270-281.e4. doi: 10.1016/j.str.2017.12.012. Epub 2018 Jan 18.

9.

Structures of β-klotho reveal a 'zip code'-like mechanism for endocrine FGF signalling.

Lee S, Choi J, Mohanty J, Sousa LP, Tome F, Pardon E, Steyaert J, Lemmon MA, Lax I, Schlessinger J.

Nature. 2018 Jan 25;553(7689):501-505. doi: 10.1038/nature25010. Epub 2018 Jan 17.

10.

EGFR Ligands Differentially Stabilize Receptor Dimers to Specify Signaling Kinetics.

Freed DM, Bessman NJ, Kiyatkin A, Salazar-Cavazos E, Byrne PO, Moore JO, Valley CC, Ferguson KM, Leahy DJ, Lidke DS, Lemmon MA.

Cell. 2017 Oct 19;171(3):683-695.e18. doi: 10.1016/j.cell.2017.09.017. Epub 2017 Oct 5.

11.

Dimerization of Tie2 mediated by its membrane-proximal FNIII domains.

Moore JO, Lemmon MA, Ferguson KM.

Proc Natl Acad Sci U S A. 2017 Apr 25;114(17):4382-4387. doi: 10.1073/pnas.1617800114. Epub 2017 Apr 10.

12.

Molecular determinants of KA1 domain-mediated autoinhibition and phospholipid activation of MARK1 kinase.

Emptage RP, Lemmon MA, Ferguson KM.

Biochem J. 2017 Feb 1;474(3):385-398. doi: 10.1042/BCJ20160792. Epub 2016 Nov 22.

13.

Overcoming resistance to HER2 inhibitors through state-specific kinase binding.

Novotny CJ, Pollari S, Park JH, Lemmon MA, Shen W, Shokat KM.

Nat Chem Biol. 2016 Nov;12(11):923-930. doi: 10.1038/nchembio.2171. Epub 2016 Sep 5.

14.

Deletion Mutations Keep Kinase Inhibitors in the Loop.

Freed DM, Park JH, Radhakrishnan R, Lemmon MA.

Cancer Cell. 2016 Apr 11;29(4):423-425. doi: 10.1016/j.ccell.2016.03.017.

15.

The Dark Side of Cell Signaling: Positive Roles for Negative Regulators.

Lemmon MA, Freed DM, Schlessinger J, Kiyatkin A.

Cell. 2016 Mar 10;164(6):1172-1184. doi: 10.1016/j.cell.2016.02.047. Review.

16.

The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma.

Infarinato NR, Park JH, Krytska K, Ryles HT, Sano R, Szigety KM, Li Y, Zou HY, Lee NV, Smeal T, Lemmon MA, Mossé YP.

Cancer Discov. 2016 Jan;6(1):96-107. doi: 10.1158/2159-8290.CD-15-1056. Epub 2015 Nov 10.

17.

EGFR mutations cause a lethal syndrome of epithelial dysfunction with progeroid features.

Ganetzky R, Finn E, Bagchi A, Zollo O, Conlin L, Deardorff M, Harr M, Simpson MA, McGrath JA, Zackai E, Lemmon MA, Sondheimer N.

Mol Genet Genomic Med. 2015 Sep;3(5):452-8. doi: 10.1002/mgg3.156. Epub 2015 Jun 4.

18.

Ligand regulation of a constitutively dimeric EGF receptor.

Freed DM, Alvarado D, Lemmon MA.

Nat Commun. 2015 Jun 10;6:7380. doi: 10.1038/ncomms8380.

19.

Comparison of Saccharomyces cerevisiae F-BAR domain structures reveals a conserved inositol phosphate binding site.

Moravcevic K, Alvarado D, Schmitz KR, Kenniston JA, Mendrola JM, Ferguson KM, Lemmon MA.

Structure. 2015 Feb 3;23(2):352-63. doi: 10.1016/j.str.2014.12.009. Epub 2015 Jan 22.

20.

ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma.

Bresler SC, Weiser DA, Huwe PJ, Park JH, Krytska K, Ryles H, Laudenslager M, Rappaport EF, Wood AC, McGrady PW, Hogarty MD, London WB, Radhakrishnan R, Lemmon MA, Mossé YP.

Cancer Cell. 2014 Nov 10;26(5):682-94. doi: 10.1016/j.ccell.2014.09.019. Epub 2014 Nov 10.

Supplemental Content

Loading ...
Support Center